Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans

Williams WB, Alam SM, Ofek G, Erdmann N, Montefiori DC, Seaman MS, Wagh K, Korber B, Edwards RJ, Mansouri K, Eaton A, Cain DW, Martin M, Hwang J, Arus-Altuz A, Lu X, Cai F, Jamieson N, Parks R, Barr M, Foulger A, Anasti K, Patel P, Sammour S, Parsons RJ, Huang X, Lindenberger J, Fetics S, Janowska K, Niyongabo A, Janus BM, Astavans A, Fox CB, Mohanty I, Evangelous T, Chen Y, Berry M, Kirshner H, Van Itallie E, Saunders KO, Wiehe K, Cohen KW, McElrath MJ, Corey L, Acharya P, Walsh SR, Baden LR, Haynes BF. Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans. Cell. 2024 May 14:S0092-8674(24)00459-8. doi: 10.1016/j.cell.2024.04.033. Epub ahead of print. PMID: 38761800.

Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial

Frank I, Li SS, Grunenberg N, Overton ET, Robinson ST, Zheng H, Seaton KE, Heptinstall JR, Allen MA, Mayer KH, Culver DA, Keefer MC, Edupuganti S, Pensiero MN, Mehra VL, De Rosa SC, Morris DE, Wang S, Seaman MS, Montefiori DC, Ferrari G, Tomaras GD, Kublin JG, Corey L, Lu S; HVTN 124 Study Team. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial. Lancet HIV. 2024 May;11(5):e285-e299. doi: 10.1016/S2352-3018(24)00036-5. PMID: 38692824.

A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope

Joshi VR, Claiborne DT, Pack ML, Power KA, Newman RM, Batorsky R, Bean DJ, Goroff MS, Lingwood D, Seaman MS, Rosenberg E, Allen TM.2024.A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope. J Virol98:e01720-23.https://doi.org/10.1128/jvi.01720-23

Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques

Lim SY, Lee J, Osuna CE, Vikhe P, Schalk DR, Chen E, Fray E, Kumar M, Schultz-Darken N, Rakasz E, Capuano S, Ladd RA, Gil HM, Evans DT, Jeng EK, Seaman M, Martin M, Van Dorp C, Perelson AS, Wong HC, Siliciano JD, Siliciano R, Safrit JT, Nixon DF, Soon-Shiong P, Nussenzweig M, Whitney JB. Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques. Science. 2024 Mar 8;383(6687):1104-1111. doi: 10.1126/science.adf7966. Epub 2024 Feb 29. PMID: 38422185; PMCID: PMC11022498.

A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope

Joshi VR, Claiborne DT, Pack ML, Power KA, Newman RM, Batorsky R, Bean DJ, Goroff MS, Lingwood D, Seaman MS, Rosenberg E, Allen TM.2024.A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope. J Virol98:e01720-23.https://doi.org/10.1128/jvi.01720-23

SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency

Li Y, Choudhary MC, Regan J, Boucau J, Nathan A, Speidel T, Liew MY, Edelstein GE, Kawano Y, Uddin R, Deo R, Marino C, Getz MA, Reynolds Z, Barry M, Gilbert RF, Tien D, Sagar S, Vyas TD, Flynn JP, Hammond SP, Novack LA, Choi B, Cernadas M, Wallace ZS, Sparks JA, Vyas JM, Seaman MS, Gaiha GD, Siedner MJ, Barczak AK, Lemieux JE, Li JZ. SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci Transl Med. 2024 Jan 24;16(731):eadk1599. doi: 10.1126/scitranslmed.adk1599. Epub 2024 Jan 24. PMID: 38266109.

Circularized Nanodiscs for Multivalent Mosaic Display of SARS-CoV-2 Spike Protein Antigens

Mabrouk MT, Zidan AA, Aly N, Mohammed MT, Ghantous F, Seaman MS, Lovell JF, Nasr ML. Circularized Nanodiscs for Multivalent Mosaic Display of SARS-CoV-2 Spike Protein Antigens. Vaccines (Basel). 2023 Oct 28;11(11):1655. doi: 10.3390/vaccines11111655. PMID: 38005987; PMCID: PMC10675430.

Mpox infection protects against re-challenge in rhesus macaques

Aid M, Sciacca M, McMahan K, Hope D, Liu J, Jacob-Dolan C, Powers O, Barrett J, Wu C, Mutoni A, Murdza T, Richter H, Velasco J, Teow E, Boursiquot M, Cook A, Orekov T, Hamilton M, Pessaint L, Ryan A, Hayes T, Martinot AJ, Seaman MS, Lewis MG, Andersen H, Barouch DH. Mpox infection protects against re-challenge in rhesus macaques. Cell. 2023 Oct 12;186(21):4652-4661.e13. doi: 10.1016/j.cell.2023.08.023. Epub 2023 Sep 20. PMID: 37734373; PMCID: PMC10591870.

Delayed and Attenuated Antibody Responses to Coronavirus Disease 2019 Vaccination With Poor Cross-Variant Neutralization in Solid-Organ Transplant Recipients—A Prospective Longitudinal Study

Liew MY, Mathews JI, Li A, Singh R, Jaramillo SA, Weiss ZF, Bowman K, Ankomah PO, Ghantous F, Lewis GD, Neuringer I, Bitar N, Lipiner T, Dighe AS, Kotton CN, Seaman MS, Lemieux JE, Goldberg MB. Delayed and Attenuated Antibody Responses to Coronavirus Disease 2019 Vaccination With Poor Cross-Variant Neutralization in Solid-Organ Transplant Recipients-A Prospective Longitudinal Study. Open Forum Infect Dis. 2023 Aug 10;10(8):ofad369. doi: 10.1093/ofid/ofad369. PMID: 37577118; PMCID: PMC10414143.

Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage

Wagh K, Seaman MS. Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage. Curr Opin HIV AIDS. 2023 Jul 1;18(4):164-170. doi: 10.1097/COH.0000000000000800. Epub 2023 May 19. PMID: 37249911; PMCID: PMC10256304.